Consolidated Financial Statements **March 31, 2018**



June 15, 2018

Independent Auditor's Report

To the Board of Directors of Sinai Health System Foundation

We have audited the accompanying consolidated financial statements of Sinai Health System Foundation, which comprise the consolidated statement of financial position as at March 31, 2018 and the consolidated statements of operations, changes in fund balances and cash flows for the year then ended, and the related notes, which comprise a summary of significant accounting policies and other explanatory information.

Management's responsibility for the consolidated financial statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

PricewaterhouseCoopers LLP PwC Tower, 18 York Street, Suite 2600, Toronto, Ontario, Canada M5J 0B2 T: +1 416 863 1133, F: +1 416 365 8215



Opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Sinai Health System Foundation as at March 31, 2018 and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Chartered Professional Accountants, Licensed Public Accountants

Pricewaterhouse Coopers LLP

Consolidated Statement of Financial Position As at March 31, 2018

	2018 \$	201
Assets		
Current assets Cash Accounts receivable Prepaid expenses	69,942,785 846,838 49,858	32,327,46 280,13 40,60
Investments (note 3)	74,119 70,913,600	30,24 32,678,44
Investments (note 3)	76,453,741	96,865,19
Investment in The Sinai Trust 2017 (note 4)	70,700,771	90,000,19
Capital assets (note 5)	116,157	38,72
Capital accord (note of	147,483,498	129,582,37
Liabilities	117,100,100	120,002,070
Current liabilities Bank indebtedness (note 6) Accounts payable and accrued liabilities Derivative liability	5,000,000 854,840	5,500,000 324,615 103,537
Due to Sinai Health System (note 7) Deferred revenue	2,034,369 559,258	2,463,175
	8,448,467	8,391,327
Due to Sinai Health System (note 7)	4,721,343	4,745,628
Employee future benefits (note 8)	71,000	37,000
Other long-term liabilities		4,065
	13,240,810	13,178,020
Fund Balances		
General Fund (note 9)	(12,785,761)	(13,010,894
Restricted Fund	37,515,782	22,313,416
Endowment Fund (note 10)	109,512,667	107,101,828
	134,242,688	116,404,350
	147,483,498	129,582,370
Commitments (note 16) Approved by the Board of Directors		
Director		Direct

Consolidated Statement of Operations

For the year ended March 31, 2018

				2018	2017
	General Fund \$	Restricted Fund \$	Endowment Fund \$	Total \$	Total \$
Income Donations, bequests and contributions Events revenue Other revenue Interest	8,018,639 660,842 1,172,951 466,700	24,618,442 3,249,364 - 104,353	3,033,316 - - 66,427	35,670,397 3,910,206 1,172,951 637,480	36,981,772 7,052,136 161,971 344,773
Investment income (loss) (note 11)	10,319,132 (12,276)	27,972,159 3,221,630	3,099,743	41,391,034 3,209,354	44,540,652 7,821,540
	10,306,856	31,193,789	3,099,743	44,600,388	52,362,192
Expenses Events Fundraising and administrative	809,344 8,198,759 9,008,103	351,074 47,156 398,230	-	1,160,418 8,245,915 9,406,333	1,750,475 8,981,974 10,732,449
Surplus before the undernoted	1,298,753	30,795,559	3,099,743	35,194,055	41,629,743
Income from The Sinai Trust 2017 (note 4)	1,909,136	-	-	1,909,136	-
Grants (note 12)	(1,099,414)	(18,172,839)	-	(19,272,253)	(28,503,555)
Surplus for the year	2,108,475	12,622,720	3,099,743	17,830,938	13,126,188

The accompanying notes are an integral part of these consolidated financial statements.

Consolidated Statement of Changes in Fund Balances

For the year ended March 31, 2018

				2018	2017
	General Fund \$ (note 9)	Restricted Fund \$	Endowment Fund \$ (note 10)	Total \$	Total \$
Fund balances - Beginning of year	(13,010,894)	22,313,416	107,101,828	116,404,350	103,260,162
Surplus for the year Employee future benefits	2,108,475	12,622,720	3,099,743	17,830,938	13,126,188
rémeasurement Interfund transfers (note 14)	7,400 (1,890,742)	2,579,646	(688,904)	7,400 -	18,000
Fund balances - End of year	(12,785,761)	37,515,782	109,512,667	134,242,688	116,404,350

The accompanying notes are an integral part of these consolidated financial statements.

Consolidated Statement of Cash Flows

For the year ended March 31, 2018

	2018 \$	2017 \$
Cash provided by (used in)		
Operating activities Surplus for the year Items not involving cash Amortization of capital assets Amortization of deferred lease inducements Employee future benefit expense Reinvested investment income Change in fair value of derivative Gift of short-term investments Change in fair value of investments	17,830,938 18,189 (4,065) 41,400 (1,849,297) (103,537) (43,874) (484,368)	13,126,188 31,484 (7,948) 4,700 (1,819,093) 1,098,018 (29,164) (6,064,629)
Net changes in non-cash working capital items Accounts receivable Prepaid expenses Due to Sinai Health System Accounts payable and accrued liabilities Deferred revenue	15,405,386 (566,702) (9,258) (453,091) 530,225 559,258 15,465,818	6,339,556 58,772 57,743 1,167,508 (437,551) - 7,186,028
Financing activities Repayment of bank indebtedness	(500,000)	(250,000)
Investing activities Purchase of capital assets Purchase of investments Proceeds from sale of investments	(95,620) - 22,745,119 22,649,499	(10,100) (10,376,700) 12,353,814 1,967,014
Change in cash during the year	37,615,317	8,903,042
Cash - Beginning of year	32,327,468	23,424,426
Cash - End of year	69,942,785	32,327,468
Supplementary information Interest paid	152,448	139,049

The accompanying notes are an integral part of these consolidated financial statements.

Notes to Consolidated Financial Statements **March 31, 2018**

1 Purpose of the organization

Sinai Health System Foundation (the Foundation) is incorporated under the laws of Ontario as a corporation without share capital. The Foundation receives, accumulates and distributes funds and/or the income therefrom for the advancement of medical research, education and improvement of patient care at Sinai Health System, formerly Mount Sinai Hospital (the Hospital).

The Foundation is a public foundation registered under the Income Tax Act (Canada) and as such is exempt from income taxes and able to issue donation receipts for income tax purposes under registration number 11904 8106 RR0001.

2 Summary of significant accounting policies

Basis of presentation and consolidation

These consolidated financial statements include the assets, liabilities, revenues and expenses of the Foundation and its subsidiary, the Benjamin Herbert Birstein Trust #2, in which the Foundation has effective control.

Management has prepared these consolidated financial statements in accordance with accounting standards for not-for-profit organizations (ASNPO).

The following summary of significant accounting policies is set forth to facilitate the understanding of these consolidated financial statements.

Fund accounting

The Foundation follows the restricted fund method of accounting for contributions. The Foundation ensures, as part of its fiduciary responsibilities, that all funds received with a restricted purpose are expended for the purpose for which they were provided.

For financial reporting purposes, the accounts have been classified into the following funds:

a) General Fund

The General Fund accounts for the Foundation's general fundraising, granting and administrative activities. The General Fund reports unrestricted resources available for immediate use.

b) Restricted Fund

The Restricted Fund includes those funds where resources are to be used for an identified purpose as specified by the donor, as stipulated by the fundraising appeal or as determined by the Board of Directors. Restricted donations, other than endowments, include a 10% allocation to the General Fund to fund critical needs support for the Hospital.

Notes to Consolidated Financial Statements **March 31, 2018**

c) Endowment Fund

The Endowment Fund includes those funds where either donor or Board of Directors restrictions require the principal to be maintained by the Foundation for a specified period of time.

Investments

Publicly traded securities are valued based on the closing prices and pooled funds are valued based on reported unit values. Fixed income securities not publicly traded include State of Israel bonds and debentures, which are valued based on cost plus accrued income. Transactions are recorded on a trade date basis and transaction costs are expensed as incurred.

Derivatives

The Foundation enters into forward foreign exchange contracts in order to manage its foreign currency exposure in its investment portfolio. The derivative contracts are measured at fair value until they are settled. The change in fair value of the derivatives is recorded in investment income (loss) in the consolidated statement of operations.

Investment in The Sinai Trust 2017 (the 2017 Trust)

The Foundation controls the 2017 Trust, a private enterprise that develops, operates and invests in commercial opportunities. The Foundation has chosen to use the equity method to account for its share of the annual operating results of the 2017 Trust.

Foreign currency translation

Revenue and expenses denominated in foreign currencies are translated into Canadian dollars at the transaction date. Investments and other monetary items denominated in foreign currencies are translated at the year-end rate. Translation gains and losses are included in the consolidated statement of operations.

Revenue recognition

The Foundation follows the restricted fund method of accounting for contributions, which include bequests and other donations. Bequests and other donations are recognized when received. Unrestricted contributions are recognized as revenue of the General Fund in the year received. Donor restricted contributions for specific purposes are recognized as revenue with 90% recorded in the Restricted Fund and 10% in the General Fund to support highest priority needs. Donor restricted contributions requiring the capital to be maintained permanently are recognized as revenue of the Endowment Fund.

Investment income (loss) consists of interest, dividends and changes in fair value of investments, net of safekeeping and investment counsel and other investment expenses. Investment income earned on the Endowment Fund or Restricted Fund resources that must be spent on donor-designated activities is recognized as revenue of the Restricted Fund. Investment income subject to donor restrictions stipulating that it be added to the endowment is recognized as revenue of the Endowment Fund. Unrestricted investment income earned on

Notes to Consolidated Financial Statements

March 31, 2018

Endowment Fund, Restricted Fund and General Fund resources is recognized as revenue of the General Fund. Investment losses are allocated in a manner consistent with investment income.

The Foundation recognizes revenue from special events in the year in which the event occurs.

Pledges

The Foundation records pledges as revenue when payment is received.

Contributed goods and services

Contributed goods and services are not recognized in the consolidated financial statements.

Capital assets

Purchased capital assets are recorded at cost less accumulated amortization. Amortization is provided on a straight-line basis over the estimated useful lives of the assets as follows:

Leasehold improvements	10 years
Furniture and fixtures	10 years
Computer hardware and software	3 years

When a capital asset no longer has any long-term service potential to the Foundation, the excess of its net carrying amount over any residual value is recognized as an expense in the consolidated statement of operations. A writedown is not reversed.

Financial instruments and risk management

The Foundation initially recognizes financial instruments at fair value and subsequently measures them at each reporting date as follows:

Cash	fair value
Accounts receivable	amortized cost
Derivatives	fair value
Investments	fair value
Bank indebtedness	fair value
Accounts payable and accrued liabilities	amortized cost
Due to Sinai Health System	amortized cost

Financial assets measured at amortized cost are assessed at each reporting date for indications of impairment. If such impairment exists, the asset shall be written down and the resulting impairment loss shall be recognized in the consolidated statement of operations for the year.

Notes to Consolidated Financial Statements March 31, 2018

Employee future benefits

The Foundation accrues its obligations under employee future benefit plans and the related costs when the benefits are earned through current service. The cost of post-employment benefits earned by employees is actuarially determined using the projected benefit method pro-rated on service and management's best estimates of retirement ages of employees and expected health-care and dental costs. Actuarial gains and losses arise when the accrued benefit obligations change during the year. Actuarial gains and losses are recorded directly in fund balances.

Use of estimates

The preparation of consolidated financial statements in conformity with ASNPO requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual amounts could differ from those estimates.

3 Investments

	2018 \$	2017 \$
Short-term		
Donated securities	74,119	30,245
Long-term		
Pooled funds	42,542,850	64,468,566
Bonds and debentures Equities	8,019,006	8,724,282
. Canadian	11,393,433	11,295,509
US	13,245,414	11,946,930
Other	1,125,319	313,283
State of Israel bonds	127,719	116,625
	76,453,741	96,865,195

Pooled funds consist of cash and a short-term investment totalling \$4,824,548 (2017 - \$634,142), bonds of \$19,972,187 (2017 - \$20,135,906), Canadian equities of \$6,633,019 (2017 - \$7,429,267), US equities of \$10,632,158 (2017 - \$12,428,543), international equities of \$305,232 (2017 - \$1,071,530) and alternative strategies of \$175,706 (2017 - \$22,769,178).

The investment portfolio is managed in accordance with the Foundation's policy and/or donor agreements. Investments made using endowed funds are classified as long-term.

Notes to Consolidated Financial Statements **March 31, 2018**

4 Investment in The Sinai Trust 2017

The 2017 Trust is a profit-oriented private entity, whose purpose is to develop, operate and invest in commercial activities. It was created on June 29, 2017, and began operations on September 29, 2017, when there was a transfer of several businesses by another related trust.

The audited financial statements as at March 31, 2018 (period from September 29, 2017 to March 31, 2018) of the 2017 Trust have not been issued yet. The information below reflects the financial results in the draft financial statements as reported on by the 2017 Trust's management:

	\$
Assets Liabilities	22,220,005 (21,087,665)
Equity	1,132,340
Operating results (six-month period from October 1, 2017 to March 31, 2018) Revenue	10 042 255
Cost of goods sold	10,043,355 (4,631,340)
Gross profit Operating expenses Interest income	5,412,015 (3,562,653) 59,774
Net income for the period	1,909,136
Cash flows	
Operating Financing	8,679,733 12,413,205
Investing	(12,407,149)
Increase in cash during the period	8,685,789
Investment consists of Balance - Beginning of year Foundation's share of the 2017 Trust net income Distributions by the 2017 Trust	1,909,136 (1,909,136)
Balance - End of year	

Notes to Consolidated Financial Statements **March 31, 2018**

5 Capital assets

			2018	2017
	Cost \$	Accumulated amortization \$	Net \$	Net \$
Leasehold improvements Furniture and fixtures Computer hardware and	331,626 125,784	263,265 94,101	68,361 31,683	11,537 18,809
software	400,621	384,508	16,113	8,380
	858,031	741,874	116,157	38,726

6 Bank indebtedness

The Foundation entered into a credit facility agreement with a Canadian chartered bank, which provides for a revolving operating line of credit of up to \$10,000,000, bearing interest at prime less 0.85%. As at March 31, 2018, the Foundation utilized \$5,000,000 (2017 - \$5,500,000) of the operating line of credit.

7 Related party balances and transactions

The Hospital is an independent corporation without share capital and has an independent board of directors. The Hospital is affiliated with the Foundation as a result of there being some common board members between the two organizations. Amounts owing to the Hospital include:

	2018 \$	2017 \$
Payable to the Hospital Lunenfeld-Tanenbaum Research Institute (LTRI) Other payables	4,746,343 2,009,369	4,771,343 2,437,460
Less: Current portion	6,755,712 2,034,369	7,208,803 2,463,175
·	4,721,343	4,745,628

In October 2007, an agreement was made with the Hospital to provide operating grants of \$7,700,144 to LTRI. The agreement was amended in March 2015, for which annual payments are equal to a minimum of \$25,000 plus 1% annual interest. The outstanding payable relating to this agreement is \$4,746,343 (2017 - \$4,771,343).

Notes to Consolidated Financial Statements **March 31, 2018**

The Hospital provides certain services to the Foundation and pays certain expenses on behalf of the Foundation. The Foundation reimburses the Hospital for all direct costs associated with the services provided and expenses paid. Administrative expenses of \$485,322 (2017 - \$501,531) were paid to the Hospital for office space occupied by the Foundation, which is leased on a month-to-month basis, payroll processing, human resources and information technology systems support, insurance coverage and visitors' reserved parking at the Hospital.

The Foundation manages Bridgepoint Foundation under a management services agreement. Under the agreement, the Foundation provides services that are reimbursed at regular intervals throughout the year. For the year ended March 31, 2018, the Foundation recognized as income \$37,909 (2017 - \$151,695) of such services.

The Foundation also manages Arthritis Research Foundation under a management services agreement. Under the agreement, the Foundation provides services that are reimbursed at regular intervals throughout the year. For the year ended March 31, 2018, the Foundation recognized as income \$20,000 (2017 - \$12,470) for such services.

As at August 18, 2017, the Foundation manages the 2017 Trust under a management services agreement. Under the agreement, the Foundation provides services that are reimbursed at regular intervals throughout the year. For the year ended March 31, 2018, the Foundation recognized as income \$40,000 (2017 - \$nil) for such services.

In addition, there is an amount of \$492,085 (2017 - \$nil) in accounts receivable from the Sinai Trust 2017 which relates to distributions receivable.

8 Employee future benefits

The Healthcare of Ontario Pension Plan (HOOPP) is a multi-employer, defined benefit pension plan (the Plan). Enrolment in HOOPP is mandatory for the Foundation's full-time staff on hire date and part-time staff employees may qualify for optional membership. Contributions made to the Plan during the year by the Foundation amounted to \$400,932 (2017 - \$441,073) and are included in fundraising and administrative expenses on the consolidated statement of operations. The most recent actuarial valuation of the Plan as at December 31, 2016 indicates the Plan has a 122% surplus in disclosed actuarial assets and is fully funded on a solvency basis.

Certain retired employees of the Foundation are entitled to non-pension post-employment benefits such as health-care, dental, life insurance and other benefits. The Foundation has accrued \$71,000 (2017 - \$37,000) for its estimated obligations based on an actuarial valuation performed in March 2018.

Notes to Consolidated Financial Statements **March 31, 2018**

9 General Fund

	2018 \$	2017 \$
Unrestricted Invested in capital assets	(12,901,918) 116,157	(13,049,620) 38,726
	(12,785,761)	(13,010,894)

The unrestricted deficiency has arisen as a result of a shortfall of funds directed to LTRI from operating and unrestricted funds in prior years to meet the budgetary needs of LTRI.

10 Endowment Fund

Endowments consist of externally restricted donations received by the Foundation and internal resources transferred by the Board of Directors, in the exercise of its discretion. With respect to the latter case, the Board of Directors may have the right to subsequently decide to remove the designation. The endowment principal is required to be maintained intact over time, subject to the Foundation's endowment policy.

Investment income generated from endowments must be used in accordance with the various purposes established by the donors or the Board of Directors. The Foundation ensures, as part of its fiduciary responsibilities, that all funds received with a restricted purpose are expended for the purpose for which they were provided.

The Foundation's endowment policy, for endowments other than the Lunenfeld Endowment Fund, has been established with the objective of protecting the value of the endowments by limiting the amount of income made available for spending to the payout amount and requiring the reinvestment of income not made available for payout, with the objective of increasing the combined value of donated funds and cumulative investment returns at the rate of inflation or greater, over time (preservation of capital). The payout amount is calculated on the opening fund balance and made available for spending restricted to the purposes set out in the donor agreement, if applicable, or as stipulated by the Board of Directors. The investment policy has established a minimum target rate of return objective as the sum of the payout rate and the inflation rate, with the aim of providing steady, predictable investment returns. The payout amount made available for spending is reviewed and set by the Board of Directors annually. For 2018, the payout amount was set at 5.0% (2017 - 5.0%). The Lunenfeld Endowment Fund has a payout rate of actual investment income earned during the year.

In any particular year, should net investment income be insufficient to satisfy the payout amount set by the Board of Directors, or if the investment return is negative, the payout amount is funded by the accumulated reinvested income in the Endowment Fund. In general, for individual endowment funds without sufficient accumulated reinvestment income, endowment capital is used in the current year. This amount is expected to be recovered by future net investment income.

In fiscal 2018, investment income of \$3,209,354 (net of fees and expenses of \$264,248) (2017 - \$7,821,540 (net of fees and expenses of \$200,074)) was earned on endowment funds. The payout amount recorded in the Restricted Fund at \$3,221,630 (2017 - \$2,910,062) consists of the payout amount of 4.0% (2017 - 4.0%) of non-Lunenfeld endowment funds of nil% (2017 - 1.6%) of Lunenfeld endowment funds. The payout amount

Notes to Consolidated Financial Statements **March 31, 2018**

recorded in the General Fund was \$863,042 (2017 - \$794,183), calculated as 1.0% (2017 - 1.0%) of non-Lunenfeld endowment funds. The remaining \$nil (2017 - \$4,117,295) represents the preservation of capital on externally restricted endowments, which was recorded as investment income on externally restricted endowments.

Major categories of restrictions on fund balances are as follows:

	2018 \$	2017 \$
Endowments, income from which must be used for research purposes	76,548,356	75,720,096
Endowments, income from which must be used for other restricted purposes Funds restricted for research endowed by the Board of	32,826,723	31,242,439
Directors	137,588	139,293
	109,512,667	107,101,828

11 Investment income (loss)

				2018	2017
	General Fund \$	Restricted Fund \$	Endowment Fund \$	Total \$	Total \$
Investment income on Endowment Fund Change in fair value of investments	105,015 (117,291)	2,112,671 1,108,959	- 264,248	2,217,686 1,255,916	2,200,164 5,821,450
Less: Investment and custodian fees	(12,276)	3,221,630	264,248 (264,248)	3,473,602 (264,248)	8,021,614 (200,074)
Net investment income (loss)	(12,276)	3,221,630	-	3,209,354	7,821,540

12 Grants

The grants to the Hospital were as follows:

	2018 \$	2017 \$
Capital, clinical and other LTRI	16,063,721 3,208,532	18,278,543 10,225,012
	19,272,253	28,503,555

Notes to Consolidated Financial Statements March 31, 2018

13 Advance from the Endowment Fund

In fiscal 2013, the Foundation provided a \$10,000,000 advance on future grants to the Hospital to support the operations of LTRI drawn from the Endowment Fund, as permitted by the endowment agreement and granted through the General Fund. The General Fund will repay the Endowment Fund through future donations and annual surpluses. As at March 31, 2018, the remaining balance to be repaid is \$4,040,414 (2017 - \$4,903,456).

14 Interfund transfers

In fiscal 2018, the Foundation transferred \$2,683,930 from the General Fund to the Restricted Fund for internally restricted donations. The Endowment Fund transferred \$793,087 to the General Fund, which represents a shortfall in the Administration fee from accumulated investment income. The Restricted Fund transferred \$104,184 to the Endowment Fund for prior year restricted donations received, which were subsequently converted to endowed funds by the donors.

15 Pledges receivable

At the end of the fiscal year, pledges receivable by the Foundation are as follows:

	\$
2018/2019 2019/2020 2020/2021 2021 and thereafter	34,572,392 17,942,965 14,978,080 49,191,310
	116,684,747

16 Commitments

From time to time, the Foundation may enter into arrangements whereby it is required to match amounts donated on a best efforts basis over an unspecified period. As at March 31, 2018, there was \$366,796 (2017 - \$366,796) of such amounts to be funded. In addition, there exists a commitment to match the annual payout for joint Sinai Health System-University of Toronto endowed chairs based on the closing market value of the investments at the beginning of each fiscal year. The match amount for the next fiscal year has been calculated at \$496,114. Since the match is based on the market value of investments, the amount in future years will fluctuate and is expected to increase over the long term.

17 Financial instruments

The Foundation is exposed to various financial risks through its transactions in financial instruments.

Currency risk

The Foundation is exposed to foreign currency risk with respect to its investments denominated in foreign currencies, including the underlying investments of its pooled funds denominated in foreign currencies,

Notes to Consolidated Financial Statements **March 31, 2018**

because the fair value and future cash flows will fluctuate due to changes in the relative value of foreign currencies against the Canadian dollar.

Credit risk

The Foundation is exposed to credit risk in connection with its short-term and fixed income investments because of the risk that one party to the financial instrument may cause a financial loss for the other party by failing to discharge an obligation. To manage this risk, the Foundation has an investment policy, which includes a target mix of investment types and concentration limits designed to achieve the optimum return within reasonable risk tolerances.

Interest rate risk

The Foundation is exposed to interest rate risk with respect to its investments in fixed income investments and a pooled fund that holds fixed income securities, because the fair value will fluctuate due to changes in market interest rates.

Other price risk

The Foundation is exposed to other price risk through changes in market prices, other than changes arising from interest rate or currency risk, in connection with its investments in equity securities and pooled funds. To manage this risk, the Foundation invests in a target mix of investment types in accordance with its investment policy.

18 Comparative figures

Certain comparative figures have been reclassified to conform to the current year's financial statement presentation.